+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019-2027

  • ID: 4851160
  • Report
  • April 2019
  • Region: Global
  • 199 pages
  • Transparency Market Research
1 of 2

Viral Vector & Plasmid DNA Manufacturing Market: Overview

This report analyzes the current and future scenario of the global viral vector & plasmid DNA manufacturing market for the period 2019 to 2027. Increase in prevalence and incidence rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with rare disorders, and raised acceptance for comparatively newer treatment options in developing countries are likely to be major drivers of the global viral vector & plasmid DNA manufacturing market during the forecast period. 

The viral vector & plasmid DNA manufacturing market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on type, application, disease, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the viral vector & plasmid DNA manufacturing market. 

Viral Vector & Plasmid DNA Manufacturing Market: Key Segments

Based on type, the global viral vector & plasmid DNA manufacturing market has been segmented into lentivirus, adenovirus, adeno-Associated Virus (AAV), plasmid DNA, and others. In terms of application, the global viral vector & plasmid DNA manufacturing market has been divided into gene therapy, vaccinology, and others. Based on disease, the market has been segregated into genetic disorders, cancer, infectious disease, and others. In terms of end-user, the market has been bifurcated into biotech companies and research institutes. The market size and forecast for each of these segments have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. 

Viral Vector & Plasmid DNA Manufacturing Market: Regional Outlook

In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in the Report

The report also profiles major players operating in the global viral vector & plasmid DNA manufacturing market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza. The global viral vector & plasmid DNA manufacturing market has been segmented as below:

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Viral Vector & Plasmid DNA Manufacturing Market

4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, 2017-2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Top 3 players operating in the market space
5.2. Key Mergers & Acquisitions
5.2. List of Manufacturer by Location of Manufacturing Facility and Type of Vector Production

6. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
6.3.1. Retroviruses
6.3.2. Adenoviruses
6.3.3. Adeno-associated Viruses
6.3.4. Plasmid DNA
6.3.5. Others
6.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type

7. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
7.3.1. Gene Therapy
7.3.2. Vaccinology
7.3.3. Others
7.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application

8. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Disease
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
8.3.1. Genetic Disorders
8.3.2. Cancer
8.3.3. Infectious Disease
8.3.4. Others
8.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease

9. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
9.3.1. Biotech Companies
9.3.2. Research Institutes
9.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user

10. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Region

11. North America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
11.2.1. Retroviruses
11.2.2. Adenoviruses
11.2.3. Adeno-associated Viruses
11.2.4. Plasmid DNA
11.2.5. Others
11.3. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
11.3.1. Gene Therapy
11.3.2. Vaccinology
11.3.3. Others
11.4. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
11.4.1. Genetic Disorders
11.4.2. Cancer
11.4.3. Infectious Disease
11.4.4. Others
11.5. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
11.5.1. Biotech Companies
11.5.2. Research Institutes
11.6. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country, 2017-2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
11.7.1. by Type
11.7.2. by Application
11.7.3. by Disease
11.7.4. by End-user
11.7.5. by Country

12. Europe Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
12.2.1. Retroviruses
12.2.2. Adenoviruses
12.2.3. Adeno-associated Viruses
12.2.4. Plasmid DNA
12.2.5. Others
12.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
12.3.1. Gene Therapy
12.3.2. Vaccinology
12.3.3. Others
12.4. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
12.4.1. Genetic Disorders
12.4.2. Cancer
12.4.3. Infectious Disease
12.4.4. Others
12.5. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
12.5.1. Biotech Companies
12.5.2. Research Institutes
12.6. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
12.7.1. by Type
12.7.2. by Application
12.7.3. by Disease
12.7.4. by End-user
12.7.5. by Country/Sub-region

13. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
13.2.1. Retroviruses
13.2.2. Adenoviruses
13.2.3. Adeno-associated Viruses
13.2.4. Plasmid DNA
13.2.5. Others
13.3. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
13.3.1. Gene Therapy
13.3.2. Vaccinology
13.3.3. Others
13.4. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
13.4.1. Genetic Disorders
13.4.2. Cancer
13.4.3. Infectious Disease
13.4.4. Others
13.5. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
13.5.1. Biotech Companies
13.5.2. Research Institutes
13.6. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
13.7.1. by Type
13.7.2. by Application
13.7.3. by Disease
13.7.4. by End-user
13.7.5. by Country/Sub-region

14. Latin America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
14.2.1. Retroviruses
14.2.2. Adenoviruses
14.2.3. Adeno-associated Viruses
14.2.4. Plasmid DNA
14.2.5. Others
14.3. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
14.3.1. Gene Therapy
14.3.2. Vaccinology
14.3.3. Others
14.4. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
14.4.1. Genetic Disorders
14.4.2. Cancer
14.4.3. Infectious Disease
14.4.4. Others
14.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
14.5.1. Biotech Companies
14.5.2. Research Institutes
14.6. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
14.7.1. by Type
14.7.2. by Application
14.7.3. by Disease
14.7.4. by End-user
14.7.5. by Country/Sub-region

15. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
15.2.1. Retroviruses
15.2.2. Adenoviruses
15.2.3. Adeno-associated Viruses
15.2.4. Plasmid DNA
15.2.5. Others
15.3. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
15.3.1. Gene Therapy
15.3.2. Vaccinology
15.3.3. Others
15.4. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
15.4.1. Genetic Disorders
15.4.2. Cancer
15.4.3. Infectious Disease
15.4.4. Others
15.5. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
15.5.1. Biotech Companies
15.5.2. Research Institutes
15.6. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
15.7.1. by Type
15.7.2. by Application
15.7.3. by Disease
15.7.4. by End-user
15.7.5. by Country/Sub-region

16. Competition Landscape
16.1. Market Player - Competition Matrix (by Tier and Size of companies)
16.2. Company Profiles
16.2.1. Lonza
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Product Portfolio
16.2.1.3. SWOT Analysis
16.2.1.4. Financial Overview
16.2.1.5. Strategic Overview
16.2.2. Catapult
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Product Portfolio
16.2.2.3. SWOT Analysis
16.2.2.4. Financial Overview
16.2.2.5. Strategic Overview
16.2.3. uniQure N.V.
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Product Portfolio
16.2.3.3. SWOT Analysis
16.2.3.4. Financial Overview
16.2.3.5. Strategic Overview
16.2.4. FUJIFILM Diosynth Biotechnologies
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Product Portfolio
16.2.4.3. SWOT Analysis
16.2.4.4. Financial Overview
16.2.4.5. Strategic Overview
16.2.5. Kaneka Eurogentec S.A.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Product Portfolio
16.2.5.3. SWOT Analysis
16.2.5.4. Financial Overview
16.2.5.5. Strategic Overview
16.2.6. Oxford Biomedica
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Product Portfolio
16.2.6.3. SWOT Analysis
16.2.6.4. Financial Overview
16.2.6.5. Strategic Overview
16.2.7. Spark Therapeutics, Inc.
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Product Portfolio
16.2.7.3. SWOT Analysis
16.2.7.4. Financial Overview
16.2.7.5. Strategic Overview
16.2.8. Cobrabiologics
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Product Portfolio
16.2.8.3. SWOT Analysis
16.2.8.4. Financial Overview
16.2.8.5. Strategic Overview
16.2.9. Merck kGA
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Product Portfolio
16.2.9.3. SWOT Analysis
16.2.9.4. Financial Overview
16.2.9.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll